Evidence map›Paper›PMID 29395974›Full record

ArticleBioorganic & medicinal chemistry letters2018

Synthesis of novel (-)-epicatechin derivatives as potential endothelial GPER agonists: Evaluation of biological effects.

Viviana Sarmiento, Israel Ramirez-Sanchez, Aldo Moreno-Ulloa, Diego Romero-Perez, Daniel Chávez, Miguel Ortiz, Nayelli Najera, Jose Correa-Basurto, Francisco Villarreal, Guillermo Ceballos

Abstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Viviana SarmientoUniversidad Autónoma de Baja California, Tijuana, BC, Mexico.
Israel Ramirez-SanchezEscuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Posgrado, Mexico.
Aldo Moreno-UlloaDepartamento de Innovación Biomédica, Centro de Investigación Científica y de Educación Superior de Ensenada (CICESE), BC, Mexico.
Diego Romero-PerezUniversidad Autónoma de Baja California, Tijuana, BC, Mexico.
Daniel ChávezCentro de Graduados e Investigación en Química del Instituto Tecnológico de Tijuana, Apartado Postal 1166, Tijuana, BC 22510, Mexico.
Miguel OrtizEscuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Posgrado, Mexico.
Nayelli NajeraEscuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Posgrado, Mexico.
Jose Correa-BasurtoEscuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Posgrado, Mexico.
Francisco VillarrealUniversity of California, San Diego, School of Medicine, USA.
Guillermo CeballosEscuela Superior de Medicina del Instituto Politécnico Nacional, Sección de Posgrado, Mexico. Electronic address: gceballosr@ipn.mx.
Instituto Politécnico Nacional · MXUniversidad Autónoma de Baja California · MXCenter for Scientific Research and Higher Education at Ensenada · MXInstituto Tecnológico de Tijuana · MXUniversity of California, San Diego · US

Funding

Epicatechin and derivatives to preserve muscle structure function in diabetesR01DK098717 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HENRY, ROBERT ROY, VILLARREAL, FRANCISCO J · 2014 to 2017
$1.4M
Epicatechin treatment for sarcopeniaR21AG047326 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VILLARREAL, FRANCISCO J · 2015 to 2015
$233k
NIA NIH HHS R21 AG047326NIDDK NIH HHS R01 DK098717
6 · The paper itself

Abstract

To potentially identify proteins that interact (i.e. bind) and may contribute to mediate (-)-epicatechin (Epi) responses in endothelial cells we implemented the following strategy: 1) synthesis of novel Epi derivatives amenable to affinity column use, 2) in silico molecular docking studies of the novel derivatives on G protein-coupled estrogen receptor (GPER), 3) biological assessment of the derivatives on NO production, 4) implementation of an immobilized Epi derivative affinity column and, 5) affinity column based isolation of Epi interacting proteins from endothelial cell protein extracts. For these purposes, the Epi phenol and C3 hydroxyl groups were chemically modified with propargyl or mesyl groups. Docking studies of the novel Epi derivatives on GPER conformers at 14 ns and 70 ns demostrated favorable thermodynamic interactions reaching the binding site. Cultures of bovine coronary artery endothelial cells (BCAEC) treated with Epi derivatives stimulated NO production via Ser1179 phosphorylation of eNOS, effects that were attenuated by the use of the GPER blocker, G15. Epi derivative affinity columns yielded multiple proteins from BCAEC. Proteins were electrophoretically separated and inmmunoblotting analysis revealed GPER as an Epi derivative binding protein. Altogether, these results validate the proposed strategy to potentially isolate and identify novel Epi receptors that may account for its biological activity.

Indexed as

AnimalsBinding SitesCatechinCattleChromatography, AffinityCoronary VesselsEndothelial CellsEstrogensMolecular Docking SimulationNitric OxideNitric Oxide Synthase Type IIIReceptors, EstrogenReceptors, G-Protein-CoupledStereoisomerismStructure-Activity RelationshipCatechinEstrogensNitric OxideNitric Oxide Synthase Type IIIReceptors, EstrogenReceptors, G-Protein-CoupledAffinity chromatographyDockingeNOS(−)-EpicatechinGPER

Identifiers

PMID29395974
PMCPMC5817025
OpenAlexW2786826971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.